Esophageal Cancer – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Esophageal cancer is the seventh leading cause of death in males in the United States (U.S.). Squamous cell carcinoma is the most common histology for esophageal cancer worldwide; however, adenocarcinoma is the most predominant histology in the U.S. Early-stage esophageal cancer may be asymptomatic or present with mild nonspecific symptoms such as heartburn, atypical chest pain, or dyspepsia. Alternatively, patients may present with occult blood in the stool or iron deficiency anemia symptoms. Patients may report mild or intermittent dysphagia, odynophagia, or a foreign body sensation. These symptoms generally warrant the diagnostic evaluation, including an esophagogastroduodenoscopy (EGD) (upper endoscopy), including a diagnostic mucosal biopsy. Some early cancers were diagnosed during routine upper endoscopic surveillance for Barrett’s esophagus. The symptoms of esophageal cancer generally progress rapidly.

The overall incidence of esophageal cancer ranges between 4.7 to 5.8 per 100,000 people per year. Males had a higher incidence of E.C. than females.

The competitive landscape of Esophageal Cancer includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Esophageal Cancer across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Esophageal Cancer Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Esophageal Cancer – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Nivolumab         Ono Pharmaceutical Co. Ltd      Phase 3

2          5-Fluorouracil (5-FU)     Hoffmann-La Roche      Phase 1/2

3          anti-PD-L1 antibody       Lee's Pharmaceutical Limited     Phase 1/2

4          OBP-301          Oncolys BioPharma Inc Phase 1

5          Camrelizumab   Jiangsu HengRui Medicine Co., Ltd.       Phase 3

6          CLS2702C/CLS2702D   CellSeed Inc.    Phase 3

7          Larotinib           Sunshine Lake Pharma Co., Ltd.            Phase 1

8          Ramucirumab   Athenex, Inc.     Phase 1

9          Amivantamab    Janssen Pharmaceutical K.K.     Phase 2

10        PCA062            Novartis Pharmaceuticals          Phase 1

Continued

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more